Which peptides are most often overfilled in recent lab reports?

By Published Last reviewed 4 min read

In brief

Sermorelin leads at +10%. IGF-1 LR3 leads at +20%.

Sermorelin most often exceeds stated content by more than 10%: 224 of 318 reports (70.4%); at a 20% margin, IGF-1 LR3 leads at 121 of 249 (48.6%). These six-month database rankings are sensitive to collection coverage, with 94.1% of records drawn directly from the Freedom Diagnostics source.

Sermorelin / above +10%
70.4%
IGF-1 LR3 / above +20%
48.6%
Direct Freedom Diagnostics source
94.1%
Evidence
30,639 report records across 32 categories; dates April 29–October 29, 2026; at least 100 records per category; analyzed October 29
Limits
Nonrandom report records, not independent purchases or market prevalence. Original-source spot checks cannot rule out every extraction error or repeated assay.
The leading five categories above a 10% margin, compared at two thresholds. Sermorelin: 70.4% above +10%, 36.2% above +20%. IGF-1 LR3: 68.7% and 48.6%. Semax: 65.3% and 37.4%. Semaglutide: 63.7% and 24.9%. TB-500: 59.0% and 29.0%.
The same five categories, two thresholds. Percentages count collected report records; exact numerators and denominators are below. Neither threshold is a safety or manufacturing standard.

The counts behind the chart

We ranked 32 categories with at least 100 qualifying records each, using report dates April 29–October 29, 2026. “Most often” means the largest share above the chosen margin, rather than the greatest number of excess milligrams.

Compound categoryMore than +10%More than +20%
Sermorelin70.4%224 / 318 reports36.2%115 / 318 reports
IGF-1 LR3*68.7%171 / 249 reports48.6%121 / 249 reports
Semax65.3%535 / 819 reports37.4%306 / 819 reports
Semaglutide63.7%348 / 546 reports24.9%136 / 546 reports
TB-500†59.0%408 / 692 reports29.0%201 / 692 reports

*IGF-LR3 and IGF-1 LR3 are grouped after checking the original identities. †TB-500 remains separate from records named Thymosin Beta-4. Download the counts, rates and median differences.

Across all qualifying results, including underfills, sermorelin’s median result is 16.3% above stated, versus 19.0% for IGF-1 LR3. A category can therefore exceed a smaller margin more often while another more often exceeds a larger one.

Retatrutide exceeds +10% in 3,981/7,701 reports (51.7%); tirzepatide in 1,809/3,770 (48.0%). Neither belongs in this leading five under the chosen definition.

One collection source dominates

28,841 of 30,639 records were collected directly from the Freedom Diagnostics source. Excluding that source leaves every member of the leading five below the 100-record minimum. The graphic shows how little coverage remains for each.

Direct Freedom Diagnostics records account for 28,841 of 30,639 records, 94.1%. Excluding that source leaves 19 sermorelin, 14 IGF-1 LR3, 55 Semax, 22 semaglutide and 75 TB-500 records: each below the 100-record minimum.
Collection channels are not necessarily different laboratories: vendor libraries and community sources may also republish Freedom reports. This checks dependence on the direct collection source, not complete exclusion of that laboratory.

Among categories still eligible after that exclusion, MOTS-C leads at 57/119 (47.9%). This change shows why the main ranking cannot be treated as the odds for a vial purchased in the wider market.

Names matter, too. Leaving “IGF-LR3” separate produces 170/234 (72.6%). Grouping the 15 qualifying “IGF-1 LR3” records lowers it to 171/249 (68.7%). We combine those documented LR3 names, while retaining distinct CJC-1295 DAC forms and Adamax molecular-mass variants.

Method and source checks

We calculated 100 × (measured mass ÷ stated mass − 1) from positive, explicit mass quantities in a frozen October 29 snapshot. Blends, nonpeptides, unusable units or dates, known duplicate reports and unresolved source conflicts were excluded. Finnrick records were excluded because their stored comparison can use a batch claim rather than the sampled vial’s label. No upper overfill cap was imposed.

Collapsing possible repeats with matching source, compound, date, batch, quantities and purity preserves the first four positions; Eloralintide replaces TB-500 in fifth. Matching fields alone do not prove a shared assay. Glutathione capitalization variants were combined; other unresolved identities remained separate.

Original-report spot checks included sermorelin, 10 → 11.64 mg, Semax, 10 → 11.55 mg, and LR3 identity in the Epic Compounds and PeptidePlugs reports. They do not validate every row: extraction errors, related assays and nonrandom submission remain limitations.

The public aggregate supports recalculating these rates; the curated record-level corpus remains proprietary. For individual extremes, see five original overfill reports. For a product-specific claim, inspect its original COA.

Prepared by the TitrateLab Research Desk with AI-assisted data analysis and editorial tooling; reviewed October 29, 2026. TitrateLab collected these reports and did not perform the assays. Report a source or calculation correction.

Vendor and manufacturer names are used descriptively to identify parties in the documentary record; inclusion is not endorsement. Think a passage misrepresents the record? [email protected].